Evidence Matters in Genomic Medicine: Pharmacogenomics
New CDC blog post: Evidence matters in genomic medicine- round 4: Where are we with pharmacogenomic tests?
CDC Horizon-prioritizing method can identify gaps in genomic application guidelines.
L Li Clinical Pharmacology and Therapeutics, April 2014
L Li Clinical Pharmacology and Therapeutics, April 2014
Prioritizing genomic applications for action by level of evidence: A horizon-scanning method.
W D Dotson et al. Clinical Pharmacology and Therapeutics, April 2014
W D Dotson et al. Clinical Pharmacology and Therapeutics, April 2014
Clinical Pharmacology & Therapeutics (2014); 95 4, 368–369. doi:10.1038/clpt.2014.16
A Horizon-Prioritizing Method Can Identify Gaps Among Genomic Application Guidelines
L Li1
1Department of Medical and Molecular Genetics, School of Medicine, Indiana University, Indianapolis, Indiana, USA
Correspondence: L Li, (lali@iupui.edu)
Topof page
Abstract
In light of the increasing need by decision makers for a method of evaluating genomic applications based on the weight of evidence for their efficacy, several agencies have developed systems of classification. Here I review the horizon-scanning method for prioritizing genomics applications as described by Dotson et al. in this issue of CPT. Using the examples of the authors’ Tier 1/Green classification for KRAS and Tier 2/Yellow for TPMT, I discuss differences between the guidelines issued by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and those by the National Comprehensive Cancer Network (NCCN). Additionally, I offer suggestions regarding classification of the Tier 3/Red genomics applications and the reproducibility of the data-curating algorithm of the horizon-scanning method.
No hay comentarios:
Publicar un comentario